Condition: Recurrent Pericarditis · Sponsor: Zomagen Biosciences Ltd.
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period Cohort C will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B * A 14-day Foll…
This description comes directly from the study's public registry record.
Ventyx Clinical Trial Contact · 888-411-5176 · ClinicalTrials@ventyxbio.com
Always discuss trial participation with your own doctor first.
| Local Site #840012 | Tucson, Arizona, United States | Withdrawn |
| Local Site #840014 | Orange, California, United States | Recruiting |
| Local Site #840016 | Saint Augustine, Florida, United States | Recruiting |
| Local Site #840008 | Chicago, Illinois, United States | Recruiting |
| Local Site #840002 | Park Ridge, Illinois, United States | Withdrawn |
| Local Site #840011 | Owensboro, Kentucky, United States | Withdrawn |
| Local Site #840010 | Boston, Massachusetts, United States | Recruiting |
| Local Site #840005 | Rochester, Minnesota, United States | Recruiting |
| Local Site #840020 | New York, New York, United States | Recruiting |
| Local Site #840017 | Cleveland, Ohio, United States | Recruiting |
| Local Site #840019 | Houston, Texas, United States | Recruiting |
| Local Site #840001 | Houston, Texas, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06836232